版本:
中国

BRIEF-Bio-Path holdings presents results showing potential of BP1002

April 5 Bio Path Holdings Inc

* Bio-Path holdings presents results showing potential of BP1002 as treatment for aggressive non-hodgkin’s lymphoma

* Bio-Path - announced results of preclinical in vitro, in vivo studies supporting potential of BP1002 in treating aggressive non-hodgkin's lymphoma (nhl)

* BP1002 was shown to have strong anti-NHL activity in each of the studies Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐